Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Epigenetic SMAD3 repression in tumor-associated fibroblasts impairs fibrosis and response to the antifibrotic drug nintedanib in lung squamous cell carcinoma.

Ikemori R, Gabasa M, Duch P, Vizoso M, Bragado P, Arshakyan M, Luis IC, Marín A, Morán S, Castro M, Fuster G, Gea-Sorli S, Jauset T, Soucek L, Montuenga LM, Esteller M, Monso E, Peinado VI, Gascon P, Fillat C, Hilberg F, Reguart N, Alcaraz J.

Cancer Res. 2019 Nov 6. pii: canres.0637.2019. doi: 10.1158/0008-5472.CAN-19-0637. [Epub ahead of print]

PMID:
31694906
2.

Variable impact of three different antiangiogenic drugs alone or in combination with chemotherapy on multiple bone marrow-derived cell populations involved in angiogenesis and immunity.

Reguera-Nuñez E, Man S, Xu P, Hilberg F, Kerbel RS.

Angiogenesis. 2019 Nov;22(4):535-546. doi: 10.1007/s10456-019-09677-x. Epub 2019 Aug 28.

PMID:
31463627
3.

Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.

Terzyan SS, Shen T, Liu X, Huang Q, Teng P, Zhou M, Hilberg F, Cai J, Mooers BHM, Wu J.

J Biol Chem. 2019 Jul 5;294(27):10428-10437. doi: 10.1074/jbc.RA119.007682. Epub 2019 May 22.

PMID:
31118272
4.

Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?

Reck M, Kerr KM, Grohé C, Manegold C, Pavlakis N, Paz-Ares L, Huber RM, Popat S, Thatcher N, Park K, Hilberg F, Barrueco J, Kaiser R.

Future Oncol. 2019 Apr;15(12):1363-1383. doi: 10.2217/fon-2018-0948. Epub 2019 Feb 13. Review.

5.

Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer.

Reguera-Nuñez E, Xu P, Chow A, Man S, Hilberg F, Kerbel RS.

J Exp Clin Cancer Res. 2019 Jan 11;38(1):16. doi: 10.1186/s13046-018-0999-5.

6.

Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer.

Schiffmann LM, Fritsch M, Gebauer F, Günther SD, Stair NR, Seeger JM, Thangarajah F, Dieplinger G, Bludau M, Alakus H, Göbel H, Quaas A, Zander T, Hilberg F, Bruns CJ, Kashkar H, Coutelle O.

Br J Cancer. 2019 Jan;120(1):69-78. doi: 10.1038/s41416-018-0198-3. Epub 2018 Oct 31.

7.

Drug resistance profiles of mutations in the RET kinase domain.

Liu X, Shen T, Mooers BHM, Hilberg F, Wu J.

Br J Pharmacol. 2018 Sep;175(17):3504-3515. doi: 10.1111/bph.14395. Epub 2018 Jul 19.

8.

Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo.

Laszlo V, Valko Z, Kovacs I, Ozsvar J, Hoda MA, Klikovits T, Lakatos D, Czirok A, Garay T, Stiglbauer A, Helbich TH, Gröger M, Tovari J, Klepetko W, Pirker C, Grusch M, Berger W, Hilberg F, Hegedus B, Dome B.

Clin Cancer Res. 2018 Aug 1;24(15):3729-3740. doi: 10.1158/1078-0432.CCR-17-1507. Epub 2018 May 3.

9.

Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases.

Hilberg F, Tontsch-Grunt U, Baum A, Le AT, Doebele RC, Lieb S, Gianni D, Voss T, Garin-Chesa P, Haslinger C, Kraut N.

J Pharmacol Exp Ther. 2018 Mar;364(3):494-503. doi: 10.1124/jpet.117.244129. Epub 2017 Dec 20.

10.

Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients.

Gabasa M, Ikemori R, Hilberg F, Reguart N, Alcaraz J.

Br J Cancer. 2017 Oct 10;117(8):1128-1138. doi: 10.1038/bjc.2017.270. Epub 2017 Sep 12.

11.

BIBF1120 (Vargatef) Inhibits Preretinal Neovascularization and Enhances Normal Vascularization in a Model of Vasoproliferative Retinopathy.

Rivera JC, Noueihed B, Omri S, Barrueco J, Hilberg F, Chemtob S.

Invest Ophthalmol Vis Sci. 2015 Dec;56(13):7897-907. doi: 10.1167/iovs.15-17146.

PMID:
26670826
12.

Nintedanib Is a Highly Effective Therapeutic for Neuroendocrine Carcinoma of the Pancreas (PNET) in the Rip1Tag2 Transgenic Mouse Model.

Bill R, Fagiani E, Zumsteg A, Antoniadis H, Johansson D, Haefliger S, Albrecht I, Hilberg F, Christofori G.

Clin Cancer Res. 2015 Nov 1;21(21):4856-67. doi: 10.1158/1078-0432.CCR-14-3036. Epub 2015 Jul 23.

13.

Nintedanib: from discovery to the clinic.

Roth GJ, Binder R, Colbatzky F, Dallinger C, Schlenker-Herceg R, Hilberg F, Wollin SL, Kaiser R.

J Med Chem. 2015 Feb 12;58(3):1053-63. doi: 10.1021/jm501562a. Epub 2015 Jan 14. Review.

PMID:
25474320
14.

Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study).

Quintela-Fandino M, Urruticoechea A, Guerra J, Gil M, Gonzalez-Martin A, Marquez R, Hernandez-Agudo E, Rodriguez-Martin C, Gil-Martin M, Bratos R, Escudero MJ, Vlassak S, Hilberg F, Colomer R.

Br J Cancer. 2014 Sep 9;111(6):1060-4. doi: 10.1038/bjc.2014.397. Epub 2014 Jul 24.

15.

Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).

Roth GJ, Heckel A, Colbatzky F, Handschuh S, Kley J, Lehmann-Lintz T, Lotz R, Tontsch-Grunt U, Walter R, Hilberg F.

J Med Chem. 2009 Jul 23;52(14):4466-80. doi: 10.1021/jm900431g.

PMID:
19522465
16.

Triple angiokinase inhibition, tumour hypoxia and radiation response of FaDu human squamous cell carcinomas.

Zips D, Le K, Yaromina A, Dörfler A, Eicheler W, Zhou X, Geyer P, Hilberg F, Baumann M.

Radiother Oncol. 2009 Sep;92(3):405-10. doi: 10.1016/j.radonc.2009.04.006. Epub 2009 May 4.

PMID:
19409639
17.

Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.

Bisping G, Wenning D, Kropff M, Gustavus D, Müller-Tidow C, Stelljes M, Munzert G, Hilberg F, Roth GJ, Stefanic M, Volpert S, Mesters RM, Berdel WE, Kienast J.

Clin Cancer Res. 2009 Jan 15;15(2):520-31. doi: 10.1158/1078-0432.CCR-08-1612.

18.

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.

Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ.

Cancer Res. 2008 Jun 15;68(12):4774-82. doi: 10.1158/0008-5472.CAN-07-6307.

19.

CD44 suppresses TLR-mediated inflammation.

Kawana H, Karaki H, Higashi M, Miyazaki M, Hilberg F, Kitagawa M, Harigaya K.

J Immunol. 2008 Mar 15;180(6):4235-45.

20.

DMBT1 confers mucosal protection in vivo and a deletion variant is associated with Crohn's disease.

Renner M, Bergmann G, Krebs I, End C, Lyer S, Hilberg F, Helmke B, Gassler N, Autschbach F, Bikker F, Strobel-Freidekind O, Gronert-Sum S, Benner A, Blaich S, Wittig R, Hudler M, Ligtenberg AJ, Madsen J, Holmskov U, Annese V, Latiano A, Schirmacher P, Amerongen AV, D'Amato M, Kioschis P, Hafner M, Poustka A, Mollenhauer J.

Gastroenterology. 2007 Nov;133(5):1499-509. Epub 2007 Aug 3.

PMID:
17983803
21.

Paracrine interactions of vascular endothelial growth factor and platelet-derived growth factor in endothelial and lung cancer cells.

Reinmuth N, Rensinghoff S, Raedel M, Fehrmann N, Schwöppe C, Kessler T, Bisping G, Hilberg F, Roth GJ, Berdel W, Thomas M, Mesters RM.

Int J Oncol. 2007 Sep;31(3):621-6.

PMID:
17671690
22.

Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis.

Chaudhary NI, Roth GJ, Hilberg F, Müller-Quernheim J, Prasse A, Zissel G, Schnapp A, Park JE.

Eur Respir J. 2007 May;29(5):976-85. Epub 2007 Feb 14.

23.

Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors.

Kulimova E, Oelmann E, Bisping G, Kienast J, Mesters RM, Schwäble J, Hilberg F, Roth GJ, Munzert G, Stefanic M, Steffen B, Brandts C, Müller-Tidow C, Kolkmeyer A, Büchner T, Serve H, Berdel WE.

Mol Cancer Ther. 2006 Dec;5(12):3105-12.

24.

Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups.

Bisping G, Kropff M, Wenning D, Dreyer B, Bessonov S, Hilberg F, Roth GJ, Munzert G, Stefanic M, Stelljes M, Scheffold C, Müller-Tidow C, Liebisch P, Lang N, Tchinda J, Serve HL, Mesters RM, Berdel WE, Kienast J.

Blood. 2006 Mar 1;107(5):2079-89. Epub 2005 Nov 8.

PMID:
16278310
25.

CD44 is a determinant of inflammatory bone loss.

Hayer S, Steiner G, Görtz B, Reiter E, Tohidast-Akrad M, Amling M, Hoffmann O, Redlich K, Zwerina J, Skriner K, Hilberg F, Wagner EF, Smolen JS, Schett G.

J Exp Med. 2005 Mar 21;201(6):903-14.

26.

Adjuvant inhibition of the epidermal growth factor receptor after fractionated irradiation of FaDu human squamous cell carcinoma.

Krause M, Hessel F, Zips D, Hilberg F, Baumann M.

Radiother Oncol. 2004 Jul;72(1):95-101.

PMID:
15236881
27.
28.

Expression of the fibroblast activation protein during mouse embryo development.

Niedermeyer J, Garin-Chesa P, Kriz M, Hilberg F, Mueller E, Bamberger U, Rettig WJ, Schnapp A.

Int J Dev Biol. 2001 Apr;45(2):445-7.

29.

Targeted disruption of mouse fibroblast activation protein.

Niedermeyer J, Kriz M, Hilberg F, Garin-Chesa P, Bamberger U, Lenter MC, Park J, Viertel B, Püschner H, Mauz M, Rettig WJ, Schnapp A.

Mol Cell Biol. 2000 Feb;20(3):1089-94.

30.

CD44-deficient mice develop normally with changes in subpopulations and recirculation of lymphocyte subsets.

Protin U, Schweighoffer T, Jochum W, Hilberg F.

J Immunol. 1999 Nov 1;163(9):4917-23.

31.

Functions of c-Jun in liver and heart development.

Eferl R, Sibilia M, Hilberg F, Fuchsbichler A, Kufferath I, Guertl B, Zenz R, Wagner EF, Zatloukal K.

J Cell Biol. 1999 May 31;145(5):1049-61.

32.

How tumor cells make use of CD44.

Herrlich P, Sleeman J, Wainwright D, König H, Sherman L, Hilberg F, Ponta H.

Cell Adhes Commun. 1998;6(2-3):141-7. Review.

PMID:
9823465
33.

Generation of normal T and B lymphocytes by c-jun deficient embryonic stem cells.

Chen J, Stewart V, Spyrou G, Hilberg F, Wagner EF, Alt FW.

Immunity. 1994 Apr;1(1):65-72.

PMID:
7889400
34.

c-jun is essential for normal mouse development and hepatogenesis.

Hilberg F, Aguzzi A, Howells N, Wagner EF.

Nature. 1993 Sep 9;365(6442):179-81. Erratum in: Nature 1993 Nov 25;366(6453):368.

PMID:
8371760
36.

Embryonic stem cell virus, a recombinant murine retrovirus with expression in embryonic stem cells.

Grez M, Akgün E, Hilberg F, Ostertag W.

Proc Natl Acad Sci U S A. 1990 Dec;87(23):9202-6.

37.
38.

Retroviral mutants efficiently expressed in embryonal carcinoma cells.

Franz T, Hilberg F, Seliger B, Stocking C, Ostertag W.

Proc Natl Acad Sci U S A. 1986 May;83(10):3292-6.

39.

Supplemental Content

Loading ...
Support Center